HUMANIGEN, INC

2022 Q3 Form 10-Q Financial Statement

#000121465922010013 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.73M $47.05M $68.95M
YoY Change -67.68% -60.97% -25.77%
Cash & Equivalents $24.73M $47.00M $68.95M
Short-Term Investments
Other Short-Term Assets $1.153M $2.313M $2.287M
YoY Change -14.4% 109.51% 165.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.88M $49.36M $71.24M
YoY Change -66.76% -59.42% -27.87%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $25.88M $49.36M $71.24M
Total Long-Term Assets $90.00K $90.00K $90.00K
Total Assets $25.97M $49.45M $71.33M
YoY Change -66.68% -59.38% -27.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $53.34M $56.67M $47.87M
YoY Change 16.05% 52.15% 10.28%
Accrued Expenses $22.16M $14.40M $19.18M
YoY Change 19.14% 61.29% 236.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.839M
YoY Change
Total Short-Term Liabilities $76.39M $76.99M $71.18M
YoY Change 11.17% 53.02% 33.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $22.55M $25.19M
YoY Change -100.0% -8.46% 3.08%
Other Long-Term Liabilities $1.986M $0.00 $0.00
YoY Change -3.31% -100.0% -100.0%
Total Long-Term Liabilities $1.986M $22.55M $25.19M
YoY Change -92.0% -8.46% -11.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $76.39M $76.99M $71.18M
Total Long-Term Liabilities $1.986M $22.55M $25.19M
Total Liabilities $78.37M $99.54M $96.37M
YoY Change -18.0% 27.55% 17.77%
SHAREHOLDERS EQUITY
Retained Earnings -$686.2M -$662.5M
YoY Change 29.7%
Common Stock $119.0K $71.00K
YoY Change 20.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$52.41M -$50.09M -$25.05M
YoY Change
Total Liabilities & Shareholders Equity $25.97M $49.45M $71.33M
YoY Change -66.68% -59.38% -27.85%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07078
dei City Area Code
CityAreaCode
(973)
dei Local Phone Number
LocalPhoneNumber
200-3100
dei Security12b Title
Security12bTitle
Common Stock
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35798
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0557236
dei Entity Address Address Line1
EntityAddressAddressLine1
830 Morris Turnpike
dei Entity Address Address Line2
EntityAddressAddressLine2
4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Short Hills
dei Trading Symbol
TradingSymbol
HGEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
103660938 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47046000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70016000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2313000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
49359000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
70971000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000 usd
CY2022Q2 us-gaap Assets
Assets
49449000 usd
CY2021Q4 us-gaap Assets
Assets
71061000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
56665000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
44698000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14395000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19882000 usd
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2839000 usd
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3091000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4145000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
76990000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
68725000 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1018000 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
22547000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25006000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
99537000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
94749000 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71242938 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71242938 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64027629 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64027629 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
71000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
64000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
612347000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
587327000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-662506000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-611079000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-50088000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-23688000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49449000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71061000 usd
CY2022Q2 us-gaap Revenues
Revenues
1036000 usd
CY2021Q2 us-gaap Revenues
Revenues
1036000 usd
us-gaap Revenues
Revenues
2072000 usd
us-gaap Revenues
Revenues
1522000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26438000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63012000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43658000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122946000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3949000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8076000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8294000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13024000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
30387000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
71088000 usd
us-gaap Operating Expenses
OperatingExpenses
51952000 usd
us-gaap Operating Expenses
OperatingExpenses
135970000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29351000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-70052000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-49880000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-134448000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
768000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
746000 usd
us-gaap Interest Expense
InterestExpense
1502000 usd
us-gaap Interest Expense
InterestExpense
765000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-45000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1157000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-30149000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-70803000 usd
us-gaap Net Income Loss
NetIncomeLoss
-51427000 usd
us-gaap Net Income Loss
NetIncomeLoss
-136370000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70670971 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58843567 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68137762 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55735008 shares
us-gaap Net Income Loss
NetIncomeLoss
-51427000 usd
us-gaap Net Income Loss
NetIncomeLoss
-136370000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3178000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2381000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
380000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
187000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1358000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
629000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11967000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21878000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5487000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5750000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2072000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3019000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44819000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103784000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21849000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
130278000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1861000 usd
us-gaap Proceeds From Issuance Of Long Term Debt And Capital Securities Net
ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
24444000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21849000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
156583000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-22970000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
52799000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70016000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67737000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47046000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120536000 usd
us-gaap Interest Paid Net
InterestPaidNet
943000 usd
us-gaap Interest Paid Net
InterestPaidNet
393000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-23688000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18374000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1543000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21278000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-25049000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3475000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1635000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-30149000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-50088000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45545000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36106000 usd
CY2021Q1 hgen Stock Issued During Period Value Stock Options Exercised1
StockIssuedDuringPeriodValueStockOptionsExercised1
429000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
510000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-65567000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
17023000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
94172000 usd
CY2021Q2 hgen Stock Issued During Period Value Stock Options Exercised1
StockIssuedDuringPeriodValueStockOptionsExercised1
1432000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1871000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-70803000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
43695000 usd
us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
12800000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47000000 usd
CY2022Q2 hgen Outstanding Principal Balance
OutstandingPrincipalBalance
26700000 usd
CY2022Q2 us-gaap Interest Receivable
InterestReceivable
100000 usd
us-gaap Prepayment Fees On Advances Net
PrepaymentFeesOnAdvancesNet
400000 usd
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
71100000 usd
CY2022Q2 hgen Capital Commitments
CapitalCommitments
300000 usd
CY2022Q2 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
36500000 usd
CY2022Q2 us-gaap Other Commitment Due In Second Year
OtherCommitmentDueInSecondYear
7600000 usd
CY2022Q2 hgen Other Commitment Due After Two Year
OtherCommitmentDueAfterTwoYear
6600000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5227858 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4676182 shares
CY2020 hgen Upfront License Fee Amount
UpfrontLicenseFeeAmount
6000000 usd
CY2020 hgen Milestone License Payments
MilestoneLicensePayments
14000000 usd
CY2021Q1 hgen Milestone License Payments
MilestoneLicensePayments
6000000 usd
CY2021Q1 hgen Net Of Withholding Taxes And Other Fees And Royalties
NetOfWithholdingTaxesAndOtherFeesAndRoyalties
4500000 usd
us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
It is expected that the Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost-plus basis from an existing or future manufacturer.
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1000000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2100000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1000000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1500000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.99
CY2022Q2 us-gaap Share Price
SharePrice
2.99
CY2022Q2 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
36500000 usd
CY2022Q2 us-gaap Other Commitment Due In Second Year
OtherCommitmentDueInSecondYear
7600000 usd
CY2022Q2 hgen Other Commitment Due After Two Year
OtherCommitmentDueAfterTwoYear
6600000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4429906 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
350078 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.99
hgen Cancelledforfeited Options
CancelledforfeitedOptions
-67325 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
27025 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.64
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4685634 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.04 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0159 pure
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1635000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1871000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3178000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2381000 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9700000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2022Q2 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
4400000 usd
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
usd
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70670971 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Proceeds From Issuance Of Long Term Debt And Capital Securities Net
ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001293310

Files In Submission

Name View Source Status
0001214659-22-010013-index-headers.html Edgar Link pending
0001214659-22-010013-index.html Edgar Link pending
0001214659-22-010013.txt Edgar Link pending
0001214659-22-010013-xbrl.zip Edgar Link pending
chartpg18.jpg Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hgen-20220630.htm Edgar Link pending
hgen-20220630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hgen-20220630_def.xml Edgar Link unprocessable
hgen-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
hgen-20220630_lab.xml Edgar Link unprocessable
hgen-20220630_htm.xml Edgar Link completed
hgen-20220630_cal.xml Edgar Link unprocessable